Compare MIRM & SKYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIRM | SKYW |
|---|---|---|
| Founded | 2018 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.0B |
| IPO Year | 2019 | N/A |
| Metric | MIRM | SKYW |
|---|---|---|
| Price | $91.35 | $97.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $97.55 | ★ $124.75 |
| AVG Volume (30 Days) | ★ 836.6K | 244.1K |
| Earning Date | 02-25-2026 | 01-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 78.86 |
| EPS | N/A | ★ 10.47 |
| Revenue | $471,794,000.00 | ★ $3,978,113,000.00 |
| Revenue This Year | $54.25 | $16.39 |
| Revenue Next Year | $21.09 | $4.29 |
| P/E Ratio | ★ N/A | $9.34 |
| Revenue Growth | ★ 53.66 | 19.27 |
| 52 Week Low | $36.88 | $74.70 |
| 52 Week High | $93.70 | $135.57 |
| Indicator | MIRM | SKYW |
|---|---|---|
| Relative Strength Index (RSI) | 71.95 | 43.91 |
| Support Level | $85.98 | $95.23 |
| Resistance Level | $93.70 | $100.81 |
| Average True Range (ATR) | 3.83 | 2.66 |
| MACD | 0.95 | -0.29 |
| Stochastic Oscillator | 87.40 | 26.20 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. Generally, SkyWest provides regional flights, and utilizes its smaller, lower-cost aircraft to carry passengers that booked tickets through airlines. It partners with carriers across the world to fly and operate aircraft for a fee. SkyWest may use the carriers's brand and ground support to coordinate marketing and easily transport passengers. The company has two reportable segments: SkyWest Airlines, which generates maximum revenue, and SkyWest Leasing.